Saypha® and Juvéderm® are established hyaluronic acid dermal filler ranges used in aesthetic practice, but they differ in formulation technology, product positioning, regulatory reach, and pricing. Licensed practices comparing the two can buy Saypha wholesale through Medica Depot while evaluating how it fits alongside other HA filler options.
This Croma Saypha filler vs Juvéderm comparison looks beyond brand recognition to the practical differences that can affect product selection. It covers flagship products, range formulations, treatment areas, longevity, safety, price, and market availability.
Key Takeaways
- Saypha and Juvéderm are both HA filler families, but their individual products differ in cross-linking, formulation, and proprietary manufacturing technology.
- Both brands offer multiple formulations designed for different correction depths and treatment areas, making product-to-product comparison more useful than comparing the brands as single fillers.
- Longevity, pricing, availability, and treatment-area suitability vary across the individual products in each range.
About: Medica Depot is your trusted all-in-one supplier, offering a range of high-quality medical injectables and supplies. We offer a worry-free experience in searching for the best and most popular products on the market, like Saypha. Whether for health professionals, plastic surgeons, dermatologists, licensed estheticians, or other specialists, we can offer genuine, brand-name products you may need. With Medica Depot, we prioritize serving you better to improve the patient’s quality of life.
Croma Saypha Filler vs Juvederm: An Overview
Saypha dermal fillers, manufactured by Croma-Pharma, and Juvéderm fillers, manufactured by Allergan Aesthetics, are both hyaluronic acid-based filler families. Their shared HA foundation makes them comparable options for facial correction and volume restoration, but the manufacturers use different approaches to modifying the material for specific aesthetic applications.
Croma-Pharma uses S.M.A.R.T. and MACRO (MAtrix CROsslinking) technology across the Saypha range, while Juvéderm incorporates Allergan’s Vycross and Hylacross manufacturing technologies in different products [3][4]. These formulation differences contribute to the characteristics and intended uses of the individual fillers within each portfolio.
How Do Saypha Filler and Juvéderm Ultra Compare?
Saypha Filler contains 23 mg/ml of cross-linked HA and is designed for injection into the mid-to-deep dermis. It is intended for moderate to deep wrinkles and folds and may also be used for lip enhancement [4].
Juvéderm Ultra is a smooth-gel HA filler used for applications that include lip augmentation and perioral correction. It forms part of the wider Juvéderm portfolio, which includes formulations designed for different facial areas and levels of correction [3].
Rather than treating either flagship product as representative of its entire brand, practitioners can compare them according to treatment area, correction depth, desired outcome, and the characteristics of the individual formulation.
Gel Handling and Correction Depth
Saypha Filler functions as a mid-density option for moderate correction in the mid-to-deep dermis. Juvéderm products intended for lip and perioral treatment are formulated around the handling characteristics required for those areas.
Product selection therefore depends on factors such as injection plane, treatment area, required degree of correction, and practitioner familiarity with the gel rather than brand preference alone.
How Are the Product Ranges Structured?
Both Saypha and Juvéderm organize their portfolios around different correction depths and treatment objectives rather than relying on one filler for every indication.
The Saypha range includes Saypha RICH for superficial hydration and fine lines, Saypha Filler for moderate wrinkles in the mid-to-deep dermis, Saypha Volume for deeper volumization and contouring, and Saypha Volume Plus for areas requiring greater structural support [4].
Juvéderm follows a similar product-specific approach, with formulations ranging from softer correction options to products such as Voluma XC for midface volumization and Volux XC for jawline definition [3].
This tiered structure allows practitioners to select a formulation according to the anatomical area, injection depth, and amount of correction required. A practice may therefore use several products from one range or select formulations from both brands for different treatment needs.
How Long Do Results Typically Last?
Results with both filler ranges can vary according to the specific product, treatment area, injection depth, and individual patient factors. For that reason, longevity is better considered at the product level rather than assigned as a single duration for either Saypha or Juvéderm.
Lighter formulations used in more superficial or mobile areas may have different maintenance intervals from products designed for deeper structural correction. Deeper volumizing options such as Saypha Volume Plus and Juvéderm Voluma XC may retain correction longer because of their formulation and placement in deeper tissue planes.
Practitioners can therefore set duration expectations according to the individual filler and treatment plan rather than applying one longevity estimate to an entire brand.
Which Treatment Areas Can Each Range Address?
Saypha products are indicated across nasolabial folds, marionette lines, lips, chin and jawline, cheek and temple volume loss, and facial asymmetry correction [4]. Juvéderm’s collection covers a comparably broad set of areas of the face, with dedicated products now FDA-approved specifically for temple hollowing and jawline definition, areas historically underserved by earlier-generation fillers [3].
For clinics building out a facial rejuvenation menu across the mid and lower face, both ranges offer enough depth and volume options to build a complete treatment plan. The differentiator tends to be which specific product within each range best matches the patient’s anatomy and desired treatment interval, not the brand itself.
Safety Profiles and Injection Considerations
Safety data for both brands are available in the clinical literature. A 2023 systematic review and meta-analysis of HA filler adverse events across the facial region, covering commonly used brands including Juvéderm, found that most reported events were mild to moderate (swelling, erythema, bruising, itching, and induration) and resolved without intervention, with severe complications remaining rare [2]. A separate systematic review focused specifically on the Saypha/MACRO-technology filler portfolio reviewed eleven clinical studies totaling 947 patients and reported a consistent, predictable safety profile, with severe or serious treatment-related events occurring in only one case across all studies reviewed, and no granulomas, hypersensitivity responses, or vascular complications observed [1].
The available evidence for both ranges primarily describes mild to moderate, temporary reactions associated with HA filler treatment. Appropriate patient selection and injection technique remain important safety considerations regardless of brand. Injection depth, tissue plane, product placement, and awareness of facial vascular anatomy can all influence treatment outcomes and complication risk.
Pricing, Regulatory Reach, and Market Availability
Pricing for both brands varies by product, distributor, geographic market, and purchasing volume.
Cost per syringe may also differ according to the formulation and the amount of product required for a particular treatment area.
Saypha is generally positioned at a different price point from Juvéderm, giving clinics another consideration when building a multi-product filler menu. Juvéderm’s established patient-facing recognition, particularly in the US market, can also influence its commercial positioning.
Availability differs by region as well. Croma-Pharma distributes Saypha across numerous international markets under European regulatory pathways, while Juvéderm has a broad global distribution network and multiple products approved for specific indications in the United States [3][4]. These differences can affect which formulations are readily available to a clinic and the sourcing requirements that apply in its market.
For licensed professionals comparing their options, Medica Depot provides access to Saypha products alongside other established injectable brands.
Which Filler Fits Which Practice?
Choosing between Saypha and Juvéderm does not necessarily require a practice to commit exclusively to one range. Product selection can instead depend on the indication, treatment area, patient preferences, budget considerations, and the handling characteristics a practitioner requires.
Saypha provides formulations spanning superficial hydration, moderate wrinkle correction, and deeper volumization. Juvéderm also offers multiple treatment-specific options and may carry greater patient familiarity in markets where the brand has a strong consumer presence.
Practitioners who want to compare how Saypha performs across common treatment areas can also review Saypha filler before and after for a closer look at expected aesthetic outcomes.
Whichever products a practice selects, reliable sourcing and product traceability remain important considerations when purchasing injectable medical devices.
The contents of this page are meant for licensed medical professionals. They serve informational purposes only and are not to be taken as medical advice.
Citations
[1] Frank, Konstantin et al. “The Safety Profile of a Portfolio of Hyaluronic Acid-Based Soft Tissue Fillers Manufactured Using MACRO Technology: A Systematic Review of Clinical Evidence.” Life (Basel, Switzerland) vol. 16,1 110. 13 Jan. 2026, doi:10.3390/life16010110
[2] Colon, Jessica et al. “Adverse Events Reported From Hyaluronic Acid Dermal Filler Injections to the Facial Region: A Systematic Review and Meta-Analysis.” Cureus vol. 15,4 e38286. 29 Apr. 2023, doi:10.7759/cureus.38286
[3] AbbVie. “How JUVÉDERM® Fillers Work.” JUVÉDERM®, www.juvederm.com/how-it-works.
[4] Croma-Pharma GmbH. “Croma-Pharma Introduces Electronic Instructions for Use across the saypha® Portfolio.” Croma-Pharma, Sept. 2026, www.cromapharma.com/assets/downloads/saypha-eIFU-introduction-press-release.pdf.
This content was prepared and reviewed under our editorial guidelines , which govern how we source, verify, and update clinical and product information. Every claim is checked against peer-reviewed research, manufacturer documentation, or regulatory guidance before publication.
